Skip to Main Content

The controversy over a pricey rare-disease drug has ensnared the industry trade group for biotech companies, which is being challenged by a patent advocate to disavow “price gouging.”

In a letter to BIO chief executive Jim Greenwood, the Patients for Affordable Drugs wrote that the trade group has “an opportunity to disavow price gouging and exploitation of unrestrained market power” by Catalyst Pharmaceuticals, one of its members. The company has caused a furor over a drug with a $375,000 list price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.